New radioactive therapy targets tough cancers in early trial
Disease control
Not yet recruiting
This early-phase study tests a radioactive drug called 177Lu-DTPA-SC16.56 in people with small-cell lung cancer or neuroendocrine prostate cancer that has worsened after standard chemotherapy. The main goal is to find the safest dose and see if the treatment can control the disea…
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 01, 2026 14:20 UTC